Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ442,5443,50,68
KB476,5477,52,03
PKN42,542,571,58
Msft215215,50,00
Nokia3,5713,5745-0,61
IBM116116,860,00
Daimler AG48,84548,8551,97
PFE37,6137,871,04
23.10.2020 11:06:49
Indexy online
AD Index online
select
AD Index online
 

  • 23.10.2020 11:01:22
Genfit (Paris)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
3,58 1,01 0,04 521 398
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 23.10.2020
Popis společnosti
Obecné informace
Název společnostiGenfit SA
TickerGNFT
Kmenové akcie:Ordinary Shares
RICGNFT.PA
ISINFR0004163111
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 30.06.2020 203
Akcie v oběhu k 30.06.2020 38 858 617
MěnaEUR
Kontaktní informace
UliceParc Eurasante 885 avenue Eugene Avinee
MěstoLOOS
PSČ59120
ZeměFrance
Kontatní osoba 
Funkce kontaktní osoby 
Telefon33 320 164 000
Fax33320164001

Business Summary: Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Genfit SA revenues increased 10% to EUR5.9M. Net loss applicable to common stockholders increased 4% to EUR53M. Revenues reflect Other Operating Income increase from EUR4K to EUR519K, Revenue increase from EUR1K to EUR122K, Operating Subsidies increase of 50% to EUR3K. Higher net loss reflects Financing Charges decrease of 100% to EUR3K (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 23.10.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardJean-Francois Mouney6302.09.201915.09.1999
Chief Executive OfficerPascal Prigent-02.09.201902.09.2019
Independent Vice Chairman of the BoardXavier Guille Des Buttes7716.06.201710.04.2008
President of the Scientific Advisory Board, Member of the Management BoardBart Staels-